NCT07612917 Brain Connectivity Changes in Glioma Patients During Treatment
| NCT ID | NCT07612917 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johannes Kepler University of Linz |
| Condition | Glioma (Any Grade) in the Brain |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-05 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2026-05 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to better understand how the brain changes during the treatment of glioma. In particular, the study looks at changes in important brain areas that are responsible for functions such as movement, language, or sensation, as well as the nerve fiber pathways that connect these areas. The main question this study aims to answer is: How do important brain areas and their connections adapt and reorganize over the course of glioma treatment? Patients with glioma will undergo repeated brain imaging examinations as part of their regular medical care. These images will be analyzed over time to observe changes in brain activity and structure during different stages of therapy. By studying these changes, researchers hope to gain new insights into the brain's ability to adapt (neuroplasticity) throughout the entire course of glioma treatment.
Eligibility Criteria
Inclusion Criteria: * Patients with diffuse gliomas (WHO grade 2-4). * Age \>18 years and \<65 years. * Written participant information and informed consent provided and signed. * Signed informed consent for functional magnetic resonance imaging (fMRI). Exclusion Criteria: * Age \<18 years or \>65 years. * Pregnancy. * Contraindications to MRI, including but not limited to: * Active medical implants (e.g., pain pump, defibrillator, cardiac pacemaker), * Orthodontic braces, * Metallic tattoos, * Non-removable piercings, * Known metallic foreign bodies, * Claustrophobia. * Cerebral metastases from secondary (non-primary) tumors. * Absence of baseline BOLD functional MRI and/or baseline neurocognitive assessment. * Failure to provide written participant information and informed consent. * Karnofsky Performance Status (KPS) \<60, unless feasibility of clinical-psychological testing and BOLD fMRI is confirmed by the investigator in consultation with clinical psychology, radiology staff, and the patient.
Contact & Investigator
Raimund Kleiser, PD Dr.
STUDY CHAIR
Neuroimaging Sciences and Support Center ,Clinical Institute for Neurosciences, Institute of Neuroradiology, Kepler Unisversity Hospital Linz, Johannes Kepler University
Frequently Asked Questions
Who can join the NCT07612917 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Glioma (Any Grade) in the Brain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07612917 currently recruiting?
Yes, NCT07612917 is actively recruiting participants. Contact the research team at raimund.kleiser@kepleruniklinikum.at for enrollment information.
Where is the NCT07612917 trial being conducted?
This trial is being conducted at Linz, Austria.
Who is sponsoring the NCT07612917 clinical trial?
NCT07612917 is sponsored by Johannes Kepler University of Linz. The principal investigator is Raimund Kleiser, PD Dr. at Neuroimaging Sciences and Support Center ,Clinical Institute for Neurosciences, Institute of Neuroradiology, Kepler Unisversity Hospital Linz, Johannes Kepler University. The trial plans to enroll 20 participants.